Biotechnology Contract Manufacturing Market Size, Share, Trends, Growth Outlook

Biotechnology Contract Manufacturing Market is estimated to increase at a Compounded Annual Growth Rate of 9.2% CAGR over the forecast period from 2024 to 2030

The Biotechnology Contract Manufacturing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Service (Manufacturing, Formulation and Fill-Finish, Packaging and Labeling, Others), By Type (Biologic Drug Substance Manufacturing, Biologic Drug Product Manufacturing), By Scale of Operation (Commercial Operations, Clinical Operations), By Source (Mammalian Expression Systems, Non-Mammalian Expression Systems), By Molecule (Monoclonal Antibodies, Cell Therapy & Gene Therapy, Antibody-Drug Conjugates (ADCs), Vaccines, Therapeutic Peptides & Proteins, Others), By Indication (Oncology, Autoimmune Diseases, Cardiovascular Diseases, Metabolic Diseases, Infectious Diseases, Neurology, Others).

An Introduction to Biotechnology Contract Manufacturing Market in 2024

Biotechnology contract manufacturing services provide outsourced production capabilities to biopharmaceutical companies, enabling them to scale up manufacturing capacity, mitigate operational risks, and accelerate time-to-market for biologic drugs and therapies. In 2024, biotechnology contract manufacturing organizations (CMOs) offer a wide range of services, including process development, cell line development, upstream and downstream processing, and fill-finish operations. These CMOs specialize in manufacturing biologics such as monoclonal antibodies, recombinant proteins, gene therapies, and cell-based therapies, adhering to strict quality and regulatory standards. Biotechnology contract manufacturing allows biopharmaceutical companies to focus on research, development, and commercialization activities while leveraging the expertise and infrastructure of CMOs for manufacturing. With increasing demand for biologic drugs and personalized medicines, biotechnology contract manufacturing services play a critical role in meeting global healthcare needs, improving patient access to innovative therapies, and driving advancements in biopharmaceutical manufacturing technologies.

Market Trend: Increasing Outsourcing of Biopharmaceutical Manufacturing

One prominent trend in the biotechnology contract manufacturing market is the increasing outsourcing of biopharmaceutical manufacturing activities by pharmaceutical and biotechnology companies. With the growing complexity of biologics production processes and the need for specialized expertise and facilities, many companies are turning to contract manufacturing organizations (CMOs) to meet their manufacturing needs. Outsourcing offers several benefits, including access to advanced manufacturing technologies, cost efficiencies, and flexibility in production capacity. This trend reflects the strategic shift towards leveraging external manufacturing partners to accelerate product development timelines, reduce capital investment risks, and focus internal resources on core competencies such as research and development.

Market Driver: Expansion of Biologics Pipeline and Demand for Manufacturing Capacity

A significant driver in the biotechnology contract manufacturing market is the expansion of the biologics pipeline and the increasing demand for manufacturing capacity. As the biopharmaceutical industry continues to grow and innovate, there is a surge in the development of novel biologics drugs, including monoclonal antibodies, recombinant proteins, cell therapies, and gene therapies. This rapid expansion of the biologics pipeline creates a need for additional manufacturing capacity to meet the growing demand for commercial-scale production. Contract manufacturing organizations play a vital role in providing the necessary infrastructure, expertise, and capacity to support the manufacturing and commercialization of biologics products, driving the growth of the contract manufacturing market.

Market Opportunity: Diversification into Advanced Therapies and Emerging Markets

An emerging opportunity in the biotechnology contract manufacturing market is the diversification into advanced therapies and emerging markets. With the rise of personalized medicine and the development of innovative therapies such as cell and gene therapies, there is a growing demand for contract manufacturing services capable of handling complex and specialized production processes. Additionally, there is potential to expand contract manufacturing operations into emerging markets with growing biopharmaceutical sectors, such as Asia-Pacific and Latin America. By establishing manufacturing facilities and partnerships in these regions, contract manufacturing organizations can tap into new market opportunities, enhance their global footprint, and support the development and commercialization of biologics drugs for patients worldwide.

Biotechnology Contract Manufacturing Market Share Analysis: Cell Therapy & Gene Therapy is the fastest growing segment over the forecast period to 2030

Among the segments in the Biotechnology Contract Manufacturing Market, the Cell Therapy & Gene Therapy segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for contract manufacturing services in cell therapy and gene therapy development and production. Cell therapy and gene therapy represent cutting-edge approaches in the treatment of various diseases, including cancer, genetic disorders, and autoimmune conditions. These therapies involve the manipulation and delivery of living cells or genetic material to target tissues or organs, offering the potential for personalized and curative treatments. However, the complexity and specialized requirements of manufacturing cell-based and gene-based therapies necessitate expertise in process development, manufacturing, quality control, and regulatory compliance. Contract manufacturing organizations (CMOs) specializing in cell therapy and gene therapy offer comprehensive manufacturing services, including biologic drug substance manufacturing, biologic drug product manufacturing, formulation and fill-finish, packaging and labeling, and other ancillary services. Furthermore, the growing pipeline of cell therapy and gene therapy candidates in various therapeutic areas, coupled with increased investment and collaboration in the biotechnology sector, drives the demand for contract manufacturing services to support clinical and commercial production. As biopharmaceutical companies and research institutions seek to advance novel cell and gene therapies from preclinical development to commercialization, the Cell Therapy & Gene Therapy segment is expected to sustain its rapid growth in the Biotechnology Contract Manufacturing Market.

Biotechnology Contract Manufacturing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, AGC Inc, Boehringer Ingelheim International GmbH, Catalent Inc, Eurofins Scientific SE, FUJIFILM Holdings Corp, GenScript Biotech Corp, JSR Corp, Lonza Group Ltd, Merck KgaA, Samsung Biologics Co. Ltd, Thermo Fisher Scientific Inc, WuXi Biologics Inc

Biotechnology Contract Manufacturing Market Segmentation

By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Biotechnology Contract Manufacturing Market Companies

AbbVie Inc
AGC Inc
Boehringer Ingelheim International GmbH
Catalent Inc
Eurofins Scientific SE
FUJIFILM Holdings Corp
GenScript Biotech Corp
JSR Corp
Lonza Group Ltd
Merck KgaA
Samsung Biologics Co. Ltd
Thermo Fisher Scientific Inc
WuXi Biologics Inc

Reasons to Buy the Biotechnology Contract Manufacturing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biotechnology Contract Manufacturing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biotechnology Contract Manufacturing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Biotechnology Contract Manufacturing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Biotechnology Contract Manufacturing Market Size Outlook, $ Million, 2021 to 2030
3.2 Biotechnology Contract Manufacturing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biotechnology Contract Manufacturing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biotechnology Contract Manufacturing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biotechnology Contract Manufacturing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Biotechnology Contract Manufacturing Industry
4.2 Key Market Trends in Biotechnology Contract Manufacturing Industry
4.3 Potential Opportunities in Biotechnology Contract Manufacturing Industry
4.4 Key Challenges in Biotechnology Contract Manufacturing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Biotechnology Contract Manufacturing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Biotechnology Contract Manufacturing Market Outlook by Segments
7.1 Biotechnology Contract Manufacturing Market Outlook by Segments, $ Million, 2021- 2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

8 North America Biotechnology Contract Manufacturing Market Analysis and Outlook To 2030
8.1 Introduction to North America Biotechnology Contract Manufacturing Markets in 2024
8.2 North America Biotechnology Contract Manufacturing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biotechnology Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

9 Europe Biotechnology Contract Manufacturing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Biotechnology Contract Manufacturing Markets in 2024
9.2 Europe Biotechnology Contract Manufacturing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biotechnology Contract Manufacturing Market Size Outlook by Segments, 2021-2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

10 Asia Pacific Biotechnology Contract Manufacturing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Biotechnology Contract Manufacturing Markets in 2024
10.2 Asia Pacific Biotechnology Contract Manufacturing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biotechnology Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

11 South America Biotechnology Contract Manufacturing Market Analysis and Outlook To 2030
11.1 Introduction to South America Biotechnology Contract Manufacturing Markets in 2024
11.2 South America Biotechnology Contract Manufacturing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biotechnology Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others
12 Middle East and Africa Biotechnology Contract Manufacturing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Biotechnology Contract Manufacturing Markets in 2024
12.2 Middle East and Africa Biotechnology Contract Manufacturing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biotechnology Contract Manufacturing Market size Outlook by Segments, 2021-2030
By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
AGC Inc
Boehringer Ingelheim International GmbH
Catalent Inc
Eurofins Scientific SE
FUJIFILM Holdings Corp
GenScript Biotech Corp
JSR Corp
Lonza Group Ltd
Merck KgaA
Samsung Biologics Co. Ltd
Thermo Fisher Scientific Inc
WuXi Biologics Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Service
Manufacturing
Formulation and Fill-Finish
Packaging and Labeling
Others
By Type
Biologic Drug Substance Manufacturing
Biologic Drug Product Manufacturing
By Scale of Operation
Commercial Operations
Clinical Operations
By Source
Mammalian Expression Systems
Non-Mammalian Expression Systems
By Molecule
Monoclonal Antibodies
Cell Therapy & Gene Therapy
Antibody-Drug Conjugates (ADCs)
Vaccines
Therapeutic Peptides & Proteins
Others
By Indication
Oncology
Autoimmune Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Neurology
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)